{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:37:37Z","timestamp":1782805057763,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.bbmt.2013.06.014","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T09:02:51Z","timestamp":1372150971000},"page":"1459-1464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States"],"prefix":"10.1016","volume":"19","author":[{"given":"Song","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Haven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Senneka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dunford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Confer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.06.014_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.bbmt.2007.12.493","article-title":"Lifetime probabilities of hematopoietic stem cell transplantation in the U.S","volume":"14","author":"Nietfeld","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1702845","article-title":"Non-HLA barriers to unrelated donor stem cell transplantation","volume":"27","author":"Kollman","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbmt.2009.11.007","article-title":"Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma","volume":"16","author":"Hari","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib4","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/cncr.25297","article-title":"Access to hematopoietic stem cell transplantation: Effect of race and sex","volume":"116","author":"Joshua","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2013.06.014_bib5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/01.mlr.0000135820.44720.89","article-title":"Treatment and referral patterns for colorectal cancer","volume":"42","author":"Oliveria","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.bbmt.2013.06.014_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/94.5.334","article-title":"Racial and ethnic disparities in the receipt of cancer treatment","volume":"94","author":"Shavers","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2013.06.014_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.1994.03520070050037","article-title":"Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States","volume":"272","author":"Katz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2013.06.014_bib8","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2008.12.003","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: An evidence-based review","volume":"15","author":"Oliansky","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2007.11.002","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: An evidence-based review","volume":"14","author":"Oliansky","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib12","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1200\/JCO.2003.03.133","article-title":"Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada","volume":"21","author":"Serna","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib13","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2008-07-163212","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation","volume":"113","author":"Ringden","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib14","series-title":"Incidence & Prevalence: 2006 Chartbook on Cardiovascular and Lung Diseases","year":"2006"},{"key":"10.1016\/j.bbmt.2013.06.014_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-10-62","article-title":"Estimates of probable dementia prevalence from population-based surveys compared with dementia prevalence estimates based on meta-analyses","volume":"10","author":"Anstey","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10428194.2010.532889","article-title":"Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone\/methotrexate, cytarabine: Results from an Australian population","volume":"52","author":"Morris","year":"2011","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2013.06.014_bib17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2008-07-168625","article-title":"Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison","volume":"113","author":"Cornelissen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib19","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib20","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib21","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/cncr.20945","article-title":"Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A metaanalysis","volume":"103","author":"Yanada","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2013.06.014_bib22","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2013.06.014_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.beha.2007.02.006","article-title":"Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia","volume":"20","author":"Zenz","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib24","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.06.014_bib26","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2009-05-206821","article-title":"Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: Ready for prime time?","volume":"114","author":"Delgado","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib27","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib28","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","article-title":"Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)","volume":"108","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib29","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/10428194.2011.652108","article-title":"Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy","volume":"53","author":"Tantiworawit","year":"2012","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2013.06.014_bib31","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.hoc.2007.07.004","article-title":"New strategies for the treatment of advanced-stage Hodgkin's lymphoma","volume":"21","author":"Diehl","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2013.06.014_bib33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.hoc.2008.07.012","article-title":"Prognostic systems for lymphomas","volume":"22","author":"Johnston","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2013.06.014_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.06.014_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bmt.1702796","article-title":"Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)","volume":"27","author":"Lazarus","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2003.09.015","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission","volume":"10","author":"Vose","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.014_bib37","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.hoc.2007.08.010","article-title":"Prognostic factors and staging in multiple myeloma","volume":"21","author":"Fonseca","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2013.06.014_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.06.014_bib39","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.06.014_bib40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A\u00a0comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.06.014_bib41","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib42","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A\u00a0decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib44","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00277-003-0654-9","article-title":"Allogeneic stem cell transplantation after a fludarabine\/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia","volume":"82","author":"Kroger","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib46","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib47","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2013.06.014_bib48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.06.014_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.seminoncol.2011.04.012","article-title":"Hematopoietic stem cell transplantation for myelodysplastic syndrome: A review","volume":"38","author":"Parmar","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib51","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: Results of Southwest Oncology Group 9400 study","volume":"111","author":"Pullarkat","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib52","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.014_bib53","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trials","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2013.06.014_bib54","doi-asserted-by":"crossref","first-page":"346a","DOI":"10.1182\/blood.V112.11.346.346","article-title":"Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"112","author":"McClune","year":"2008","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113002851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113002851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:39Z","timestamp":1761057939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1083879113002851"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.06.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}